Systemic chemo-immunotherapy for advanced-stage hepatocellular carcinoma

Table 1 Composition of the PIAF regimen.

Drugs	Dose (mg/m2 body surface/d)	Route of administration	Days of use
Cisplatin	20	IV drip	Days 1-4
Doxorubicin	40	IV injection	Day 1
5-FU	400	IV drip	Days 1-4
α-INF1	5 MU/m2 body surface/d	S.C. injection	Days 1-4

¹Human recombinant α-INF-2a (Shanghai Roche Co.). Abbreviations: IV: intravenous; S.C.: subcutaneous; MU: million unit.

Table 2 Comparison of clinicopathological features between groups A and B.

	Group A (n = 8)	Group B (n = 18)
Gender (male:female)	7:1	16:2
Age (yr)	46±9	45±10
HBsAg (positive:negative)	7:1	17:1
Liver function (grade A:B)	7:1	14:4
AFP (>500 mg/L:<500 mg/L)	6:2	12:6
Primarily-treated: Recurrent	2:6	10:8
Tumor staging (III:IVa:IVb)	0:5:3	1:11:6